Article

Engineering CAR-NK cells to secrete IL15 sustains their anti-AML functionality, but is associated with systemic toxicities

2021-09-24

Abstract excerpt

<h4>Background</h4> The prognosis of patients with recurrent/refractory acute myelogenous leukemia (AML) remains poor and cell-based immunotherapies hold promise to improve outcomes. NK cells can elicit an anti-leukemic response via a repertoire of activating receptors that bind AML surface ligands. NK cell adoptive transfer is safe but thus far has shown limited anti-AML efficacy. Here, we aimed to overcome this...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4cf6aa70-ba0e-57bf-bbee-681faaedb08f
DOI: 10.1101/2021.09.23.461509

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Engineering CAR-NK cells to secrete IL15 sustains their anti-AML functionality, but is associated with systemic toxicitiesDOI 10.1101/2021.09.23.461509Read

TriLeukeVax: A CD80/IL-15/IL-15Rα Expressing Autologous AML Cell Vaccine Elicits Robust Anti-Leukemic Cytolytic ActivitySemantic proximity Read

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX ModelsSemantic proximity Read

A Novel Natural Killer Cell Expansion Technology for the Development of Cellular ImmunotherapiesSemantic proximity Read

NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against NeuroblastomaSemantic proximity Read

A Novel Feeder cell based on 4-1BBL and Membrane-bound IL-21/ IL-15 Induce Highly Expansion and Anti-tumor Effect of Natural Killer CellsSemantic proximity Read

In-depth comparative characterization identifies scalable CD123-CAR-NK cells as promising strategy to combat AMLSemantic proximity Read

Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemiaSemantic proximity Read

Modified CD15/CD16-CLL1 inhibitory CAR-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemiaSemantic proximity Read

Natural killer cell engineering for cellular therapy of cancerSemantic proximity Read

<i>Bona fide</i> cytotoxic iNKT cells with superior antitumour responses identified in mice and humansSemantic proximity Read

Adoptive NK cell therapy in AML: progress and challengesSemantic proximity Read

Recent Progress in NKG2D CAR-NK Cells for Cancer ImmunotherapySemantic proximity Read